Found 23 bookmarks
Custom sorting
Long COVID appears to be driven by ‘long infection’. Here’s what the science says
Long COVID appears to be driven by ‘long infection’. Here’s what the science says
“…in a perspective article published in the latest Medical Journal of Australia, we argue that much, if not all, long COVID appears to be driven by the virus itself persisting in the body.”
in a perspective article published in the latest Medical Journal of Australia, we argue that much, if not all, long COVID appears to be driven by the virus itself persisting in the body.
#Long Covid#Post-Acute Conditions#Viral Persistence
·theconversation.com·
Long COVID appears to be driven by ‘long infection’. Here’s what the science says
Fantastic review on chronic SARS-CoV-2 infections by virological superstars Richard Neher & Alex Sigal in Nature Microbiology. I’ll do a short overview, outline a couple minor quibbles, & defend the honor of ORF9b w/some stats & 3 striking sequences from the past week.
Fantastic review on chronic SARS-CoV-2 infections by virological superstars Richard Neher & Alex Sigal in Nature Microbiology. I’ll do a short overview, outline a couple minor quibbles, & defend the honor of ORF9b w/some stats & 3 striking sequences from the past week.
“Fantastic review on chronic SARS-CoV-2 infections by virological superstars Richard Neher & Alex Sigal in Nature Microbiology. I’ll do a short overview, outline a couple minor quibbles, & defend the honor of ORF9b w/some stats & 3 striking sequences from the past week.”
#Long Covid#Post-Acute Conditions#Viral Persistence#Discussion#analysis
·x.com·
Fantastic review on chronic SARS-CoV-2 infections by virological superstars Richard Neher & Alex Sigal in Nature Microbiology. I’ll do a short overview, outline a couple minor quibbles, & defend the honor of ORF9b w/some stats & 3 striking sequences from the past week.
If there is a viral reservoir of SARS-CoV-2 why did the Stanford Paxlovid trial fail? The drug might be insufficient, or poor penetration in some reservoirs, or inappropriate end points, etc. Dominique Salmon MD PhD
If there is a viral reservoir of SARS-CoV-2 why did the Stanford Paxlovid trial fail? The drug might be insufficient, or poor penetration in some reservoirs, or inappropriate end points, etc. Dominique Salmon MD PhD
“If there is a viral reservoir of SARS-CoV-2 why did the Stanford Paxlovid trial fail? The drug might be insufficient, or poor penetration in some reservoirs, or inappropriate end points, etc. Dominique Salmon MD PhD”
#Viral Persistence#antiviral#Long Covid#Post-Acute Conditions#Paxlovid#treatment#Dominique Salmon MD PhD#Video
·x.com·
If there is a viral reservoir of SARS-CoV-2 why did the Stanford Paxlovid trial fail? The drug might be insufficient, or poor penetration in some reservoirs, or inappropriate end points, etc. Dominique Salmon MD PhD
Towards a cure for long COVID: the strengthening case for persistently replicating SARS‐CoV‐2 as a driver of post‐acute sequelae of COVID‐19
Towards a cure for long COVID: the strengthening case for persistently replicating SARS‐CoV‐2 as a driver of post‐acute sequelae of COVID‐19
“the strengthening case for persistently replicating SARS-CoV-2 as a driver of post-acute sequelae of COVID-19”
the strengthening case for persistently replicating SARS-CoV-2 as a driver of post-acute sequelae of COVID-19
#Long Covid#Post-Acute Conditions#Viral Persistence
·onlinelibrary.wiley.com·
Towards a cure for long COVID: the strengthening case for persistently replicating SARS‐CoV‐2 as a driver of post‐acute sequelae of COVID‐19
Viral afterlife: SARS-CoV-2 as a reservoir of immunomimetic peptides that reassemble into proinflammatory supramolecular complexes | PNAS
Viral afterlife: SARS-CoV-2 as a reservoir of immunomimetic peptides that reassemble into proinflammatory supramolecular complexes | PNAS

SARS-CoV-2 peptide fragments can reassemble with dsRNA into proinflammatory complexes, amplifying immune responses.

These complexes trigger cytokine secretion in various cell types, mimicking severe COVID-19 inflammation.

#Viral Persistence#Inflammation#cytokines#immune dysregulation#Immune system#peptide fragments#Post-Acute Conditions#Long Covid
·pnas.org·
Viral afterlife: SARS-CoV-2 as a reservoir of immunomimetic peptides that reassemble into proinflammatory supramolecular complexes | PNAS
Measurement of circulating viral antigens post-SARS-CoV-2 infection in a multicohort study
Measurement of circulating viral antigens post-SARS-CoV-2 infection in a multicohort study
“The findings of this multicohort study indicate that SARS-CoV-2 antigens can be detected in the blood of a substantial proportion of individuals up to 14 months after infection. While approximately one in five asymptomatic individuals was antigen-positive, roughly half of all individuals reporting ongoing cardiopulmonary, musculoskeletal, and neurologic symptoms were antigen-positive.”
The findings of this multicohort study indicate that SARS-CoV-2 antigens can be detected in the blood of a substantial proportion of individuals up to 14 months after infection. While approximately one in five asymptomatic individuals was antigen-positive, roughly half of all individuals reporting ongoing cardiopulmonary, musculoskeletal, and neurologic symptoms were antigen-positive.
#Viral Persistence#Long Covid#Post-Acute Conditions
·clinicalmicrobiologyandinfection.com·
Measurement of circulating viral antigens post-SARS-CoV-2 infection in a multicohort study
Here is the first randomized trial to show that an antiviral can prevent Long Covid.
Here is the first randomized trial to show that an antiviral can prevent Long Covid.

“Here is the first randomized trial to show that an antiviral can prevent Long Covid.

In the PANORAMIC trial, people randomized to molnupiravir had less risk of Long Covid than people who received no antivirals

My comment in the link below. A short🧵”

#long covid#Viral Persistence#antiviral#molnupiravir#treatment#Covid Prep#analysis#Discussion
·x.com·
Here is the first randomized trial to show that an antiviral can prevent Long Covid.
SARS-CoV-2 antivirals and post-COVID-19 condition
SARS-CoV-2 antivirals and post-COVID-19 condition
“Because SARS-CoV-2 itself is the causative agent of long COVID and because viral persistence is postulated to play a major role in the pathogenesis of the condition, antivirals, which block viral replication, were seen as potential candidates for the prevention and treatment of long COVID.”
Because SARS-CoV-2 itself is the causative agent of long COVID and because viral persistence is postulated to play a major role in the pathogenesis of the condition, antivirals, which block viral replication, were seen as potential candidates for the prevention and treatment of long COVID.
#Viral Persistence#antiviral#treatment#long covid#Covid Prep#molnupiravir
·thelancet.com·
SARS-CoV-2 antivirals and post-COVID-19 condition
"The use of antivirals to reduce the risk of long COVID is grounded in the hypothesis that viral persistence and possible ongoing replication of SARS-CoV-2 are major mechanistic pathways responsible for long COVID..
"The use of antivirals to reduce the risk of long COVID is grounded in the hypothesis that viral persistence and possible ongoing replication of SARS-CoV-2 are major mechanistic pathways responsible for long COVID..

Literally living WITH Covid.

The use of antivirals to reduce the risk of long COVID is grounded in the hypothesis that viral persistence and possible ongoing replication of SARS-CoV-2 are major mechanistic pathways responsible for long COVID

#Viral Persistence#long covid#antiviral#treatment
·x.com·
"The use of antivirals to reduce the risk of long COVID is grounded in the hypothesis that viral persistence and possible ongoing replication of SARS-CoV-2 are major mechanistic pathways responsible for long COVID..
Antiviral therapies for the management of persistent coronavirus disease 2019 in immunocompromised hosts: A narrative review
Antiviral therapies for the management of persistent coronavirus disease 2019 in immunocompromised hosts: A narrative review

ANTIVIRAL THERAPIES FOR PERSISTENT COVID/LONG COVID 83% SUCCESS 70 of 84 cases with the aggravating factor of immunosuppression

The types of treatment were grouped into: Prolonged Antiviral therapy Combination Antivirals Mixed therapy: Antiviral +Antibody

#antiviral#Viral Persistence#long covid
·onlinelibrary.wiley.com·
Antiviral therapies for the management of persistent coronavirus disease 2019 in immunocompromised hosts: A narrative review
Use of total-body PET imaging to identify deep-tissue SARS-CoV-2 viral reservoirs and T cell responses in patients with Long COVID - PolyBio Research Foundation
Use of total-body PET imaging to identify deep-tissue SARS-CoV-2 viral reservoirs and T cell responses in patients with Long COVID - PolyBio Research Foundation
USE OF TOTAL-BODY PET IMAGING TO IDENTIFY DEEP-TISSUE SARS-COV-2 VIRAL RESERVOIRS AND T CELL RESPONSES IN PATIENTS WITH LONG COVID
#Long Covid#Viral Persistence
·polybio.org·
Use of total-body PET imaging to identify deep-tissue SARS-CoV-2 viral reservoirs and T cell responses in patients with Long COVID - PolyBio Research Foundation
Fulltext
Fulltext
"The presented evidence suggests that the duration of SARS-CoV-2 infection in patients can persist considerably longer than suggested"
#Viral Persistence#Long Covid
·thelancet.com·
Fulltext